Amgen/Ortho EPO arbitration
Executive Summary
Closed hearings will take place Sept. 6, 7 and 8 in Chicago. The companies entered into arbitration in January to resolve a dispute over their 1985 marketing agreement for erythropoietin. Amgen's Epogen was approved in June for the treatment of anemia associated with chronic renal failure using some of Ortho's data on predialysis patients. A PLA for Ortho's EPO product Eprex is currently pending at FDA. The agency is not expected to act on Ortho's application until the marketing dispute is resolved.
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.